News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Anthropic's record $107.3 billion IPO boosted U.S. futures and signaled strong demand for a pure-play AI listing.
  • Federal Reserve minutes show almost all policymakers expect additional rate hikes, with markets pricing at least a quarter-point in December.
  • The 10-year Treasury yield rose above 5% and the 2-year yield also climbed on tighter policy expectations.
  • Oil prices rose after reports President Trump is considering renewed strikes on Iran, increasing supply-risk concerns.
  • Toyota recalled 314,029 U.S. vehicles over potentially rupturing Takata passenger air bag inflators; dealers will replace affected parts free.
  • Take-Two Interactive shares jumped over 6% ahead of the Grand Theft Auto VI release.
  • Eli Lilly received a buy initiation as GLP-1 obesity drugs continue to drive top-line growth and free cash flow.

Latest Articles

Monarch Casino Resort Spa Earns Two More USA TODAY 10Best Readers’ Choice Awards Nominations, Including First for Best Casino Restaurant

Monarch Casino Resort Spa Earns Two More USA TODAY 10Best Readers’ Choice Awards Nominations, Including First for Best Casino Restaurant

Monarch Casino Resort Spa has earned two new nominations in the USA TODAY 10Best Readers’ Choice Awards for Best Casino Restaurant and Best Players Club. Monarch Chophouse received its first nomination in the Best Casino Restaurant category, reflecting its nationally recognized dining experience. Monarch Rewards, the company's loyalty program, was …

Scribe Therapeutics Secures $155.51 Million in Nasdaq IPO

Scribe Therapeutics Secures $155.51 Million in Nasdaq IPO

Scribe Therapeutics Inc. completed its initial public offering, generating roughly $155.51 million in gross proceeds. The Alameda, California-based clinical-stage biotechnology company sold 9,867,000 common shares at $15.00 per share, including shares issued after underwriters fully exercised their option. The offering coincided with a private plac…

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

Organogenesis Holdings Inc. announced peer-reviewed publication of a randomized controlled trial demonstrating that its regenerative medicine product Affinity™, when combined with standard care, significantly improves wound closure rates in complex venous leg ulcers compared to standard care alone. This data reinforces Affinity's clinical value and…

TFI International Announces 2026 Second Quarter Results

TFI International Announces 2026 Second Quarter Results

TFI International Inc. announced robust second quarter 2026 results, highlighted by a 12% increase in total revenue to $2.29 billion and a 29% rise in operating income to $220.4 million year-over-year. The company's net income grew 39%, and adjusted diluted EPS increased by 38%, driven by solid performance across Truckload, Logistics, and Less-Than…

Slide Insurance Holdings, Inc. Initiates Quarterly Dividend

Slide Insurance Holdings, Inc. Initiates Quarterly Dividend

Slide Insurance Holdings, Inc. has declared its first quarterly dividend of $0.07 per common share, payable in August 2026. The board emphasized this move as a sign of confidence in their business fundamentals and balance sheet strength, while maintaining capital for long-term growth. The company is a technology-driven insurer leveraging AI for opt…

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Scribe Therapeutics, a clinical-stage biotech company specializing in CRISPR-based genetic therapies targeting cardiometabolic diseases, has successfully closed an upsized IPO raising approximately $155.5 million. The offering included full exercise of underwriters' options and a concurrent private placement with Sanofi. The company aims to develop…

CBNK Reports 2Q ROA of 1.52% and EPS of $0.87

CBNK Reports 2Q ROA of 1.52% and EPS of $0.87

Capital Bancorp, Inc. (NASDAQ: CBNK) reported its second quarter 2026 results, showcasing a 1.52% return on assets and diluted earnings per share of $0.87, up 19% from the prior quarter. The company experienced robust growth in gross loans and deposits, enhanced tangible book value per share, and diversified fee income streams. Strategic investment…

HF Foods to Report Second Quarter 2026 Results on August 10, 2026

HF Foods to Report Second Quarter 2026 Results on August 10, 2026

HF Foods Group Inc., a leading distributor of international foodservice products primarily to Asian restaurants across the U.S., announced it will release its second quarter 2026 financial results on August 10, 2026, after market close. The company will host a conference call accessible via webcast to discuss the performance and outlook.

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

Denali Therapeutics announced the scheduled release of its second quarter 2026 financial results and business highlights on August 6, 2026. Management will hold a conference call and webcast to discuss these results and provide a general business update. Denali focuses on developing biotherapeutics capable of crossing the blood-brain barrier to tre…